Canadian Schizophrenia Guidelines: Schizophrenia and Other Psychotic Disorders with Coexisting Substance Use Disorders

Canadian Journal of Psychiatry

Volumn 62, Issue 9, 2017, Pages 624-634

  Crockford, David ^a   Addington, Donald ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

guidelines; psychotic disorders; schizophrenia; substance use disorders

Indexed keywords

AMFEBUTAMONE; NEUROLEPTIC AGENT; VARENICLINE;

AGE; CANADA; CLINICAL ASSESSMENT; CLINICAL OUTCOME; CONFIDENTIALITY; DETOXIFICATION; DRUG DEPENDENCE; FAMILY THERAPY; FEAR; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HOSPITAL CARE; HUMAN; HUMAN DIGNITY; INFORMED CONSENT; LANGUAGE; MEDICAL SPECIALIST; MENTAL HEALTH CARE; META ANALYSIS; NICOTINE REPLACEMENT THERAPY; PATIENT CARE; PATIENT REFERRAL; PRACTICE GUIDELINE; PRIVACY; PROFESSIONAL COMPETENCE; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SMOKING CESSATION; SOCIAL DISCRIMINATION; STIGMA; SUPPORT GROUP; SYSTEMATIC REVIEW; TREATMENT PLANNING; EVIDENCE BASED MEDICINE; PSYCHIATRIC DIAGNOSIS; STANDARDS;

CANADA; DIAGNOSIS, DUAL (PSYCHIATRY); EVIDENCE-BASED MEDICINE; HUMANS; PRACTICE GUIDELINES AS TOPIC; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS;

EID: 85029088286     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/0706743717720196     Document Type: Review

References (65)

1. Kessler RC, Nelson CB, McGonagle KA, et al. The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. Am J Orthopsychiatry. 1996; 66 (1): 17-31.
2. Reiger DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990; 264: 2511-2518.
3. de Leon J, Diaz FJ,. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 2005; 76 (2-3): 135-157.
4. Ziedonis DM, Kosten TR, Glazer WM, et al. Nicotine dependence and schizophrenia. Hosp Community Psychiatry. 1994; 45: 204-206.
5. Semple DM,. Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol. 2005; 19 (2): 187-194.
6. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007; 370: 319-328.
7. Barnes TR, Jones PB, Burke M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007; 370: 319-328.
8. Bechtold J, Hipwell A, Lewis DA, et al. Concurrent and sustained cumulative effects of adolescent marijuana use on subclinical psychotic symptoms. Am J Psychiatry. 2016; 173: 781-789.
9. Large M, Sharma S, Compton MT, et al. Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry. 2011; 68 (6): 555-561.
10. Margolese HC, Malchy L, Negrete JC, et al. Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophr Res. 2004; 67: 157-166.
11. Bartels SJ, Teague GB, Drake RE, et al. Substance abuse in schizophrenia: service utilization and costs. J Nerv Ment Dis. 1993; 181: 227-232.
12. Dixon L,. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res. 1999; 35 (suppl): S93-S100.
13. Schmidt LM, Hesse M, Lykke J,. The impact of substance use disorders on the course of schizophrenia-a 15 year follow-up study: dual diagnosis over 15 years. Schizophr Res. 2011; 130: 228-233.
14. Yucel M, Bora E, Lubman DI, et al. The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophr Bull. 2012; 38 (2): 316-330.
15. Wobrock T, Falkai P, Schneider-Axmann T, et al. Comorbid substance abuse in first-episode schizophrenia: effects on cognition and psychopathology in the EUFEST study. Schizophr Res. 2013; 147: 132-139.
16. Adan A, Arrendondo AY, Capella M, et al. Neurobiological underpinnings and modulating factors in schizophrenia spectrum disorders with a comorbid substance use disorder: a systematic review. Neurosci Biobehav Rev. 2017; 75: 361-377.
17. Arendt M, Mortensen PB, Rosenberg R, et al. Familial predisposition for psychiatric disorder: comparison of subjects treated for cannabis-induced psychosis and schizophrenia. Arch Gen Psychiatry. 2008; 65 (11): 388-398.
18. Niei-Pynttari JA, Sund R, Putkonen H, et al. Substance-induced psychoses converting into schizophrenia: a register-based study of 18,478 Finnish inpatient cases. J Clin Psychiatry. 2013; 74 (1): e94-e99.
19. Sara GE, Burgess PM, Malhi GS, et al. The impact of cannabis and stimulant disorders on diagnostic stability in psychosis. J Clin Psychiatry. 2014; 75 (4): 349-356.
20. Balderston R, Crockford D,. Management of the psychotic substance using patient. Canadian Journal of Addiction. 2014; 5 (2): 5-9.
21. The ADAPTE Collaboration. The ADAPTE process: resource toolkit for guideline adaptation. Version 2.0; 2009. Available from: http://www.g-i-n.net
22. Brouwers M, Kho ME, Browman GP, et al.on behalf of the AGREE Next Steps Consortium. AGREE II: Advancing guideline development, reporting and evaluation in healthcare. Can Med Assoc J. 2010; 182: E839-E842.
23. National Institute for Health and Care Excellence (NICE). Coexisting severe mental illness (psychosis) and substance misuse: assessment and management in healthcare settings. London (UK): NICE; 2011.
24. National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management. London (UK): NICE; 2014.
25. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington (VA): American Psychiatric Association; 2013.
26. Meis LA, Griffin JM, Greer N, et al. Couple and family involvement in adult mental health treatment: a systematic review. Clin Psychol Rev. 2013; 33: 275-286.
27. Pharoah F, Mari J, Rathbone J, et al. Family intervention for schizophrenia. Cochrane Database Syst Rev. 2010;(12): CD000088.
28. Pitschel-Walz G, Leucht S, Bauml J, et al. The effect of family interventions on relapse and rehospitalization in schizophrenia-a meta-analysis. Schizophr Bull. 2001; 27: 73-92.
29. Nolin M, Malla A, Tibbo P, et al. Early intervention for psychosis in Canada: what is the state of affairs? Can J Psychiatry. 2016; 61: 186-194.
30. Drake RE, O'Neal EL, Wallach MA,. A systemic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders. J Subst Abuse Treat. 2008; 34 (1): 123-138.
31. Brunette MF, Mueser KT,. Psychosocial interventions for the long-term management of patients with severe mental illness and co-occurring substance use disorder. J Clin Psychiatry. 2006; 67 (suppl 7): 10-17.
32. Wisdom JP, Manuel JI, Drake RE,. Substance use disorder among people with first-episode psychosis: a systemic review of course and treatment. Psychiatr Serv. 2011; 62: 1007-1012.
33. Crump C, Winkleby MA, Sundquist K, et al. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry. 2013; 170: 324-333.
34. Saha S, Chant D, McGrath J,. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007; 64: 1123-1131.
35. Morden ME, Lai Z, Goodrich D, et al. Eight-year trends of cardiometabolic morbidity and mortality in patients with schizophrenia. Gen Hosp Psychiatry. 2012; 34: 368-379.
36. Baliunas D, Patra J, Rehm J, et al. Smoking-attributable mortality and expected life years lost in Canada 2002: conclusions from prevention and policy. Chronic Dis Can. 2007; 27: 154-162.
37. Bobes J, Arango C, Garcia-Garcia M, et al. Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. Schizophr Res. 2010; 119: 101-109.
38. Kelly C, McCreadie RG,. Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland. Am J Psychiatry. 1999; 156: 1751-1757.
39. Olincy A, Young DA, Freedman R,. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol Psychiatry. 1997; 42: 1-5.
40. Tsoi DT, Porwal M, Webster AC,. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev. 2013;(2): CD007253.
41. DiClemente CC, Delahanty JC, Kofeldt MG, et al. Stage movement following a 5A's intervention in tobacco dependent individuals with serious mental illness (SMI). Addict Behav. 2011; 36: 261-264.
42. Tidey JW, Miller ME,. Smoking cessation and reduction in people with chronic mental illness. BMJ. 2015; 351: h4065.
43. Karkhane Yousefi M, Folsom TD, Fatemi SH,. A review of varenicline's efficacy and tolerability in smoking cessation studies in subjects with schizophrenia. J Addict Res Ther. 2011; suppl 4 (1): 3045.
44. Williams JM, Anthenelli RM, Morris CD, et al. A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2012; 73 (5): 654-660.
45. Thomas KH, Martin RM, Knipe DW, et al. Risk of neuropsychiatric adverse events associated with varenicline: systemic review and meta-analysis. BMJ. 2015; 350: h1109.
46. Leucht S, Tardy M, Komossa K, et al. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2012;(5): CD008016.
47. Wobrock T, Soyka M,. Pharmacotherapy of schizophrenia with comorbid substance use disorder-reviewing the evidence and clinical recommendations. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32: 1375-1385.
48. Wobrock T, Soyka M,. Pharmacotherapy of patients with schizophrenia and substance abuse. Expert Opin Pharmacother. 2009; 10 (3): 353-367.
49. Lubman DI, King JA, Castle DJ,. Treating comorbid substance use disorders in schizophrenia. Int Rev Psychiatry. 2010; 22 (2): 191-201.
50. Murthy P, Chand P,. Treatment of dual disorders. Curr Opin Psychiatry. 2012; 25: 194-200.
51. Rubio G, Martinez I, Ponce G, et al. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry. 2006; 51: 531-539.
52. Green AI, Brunette MF, Dawson R, et al. Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial. J Clin Psychiatry. 2015; 76 (10): 1359-1365.
53. Leatherman SM, Liang MH, Krystal JH, et al. Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia. J Nerv Ment Dis. 2014; 202: 13-17.
54. Swartz MS, Wagner HR, Swanson JW, et al. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. Schizophr Res. 2008; 100 (1-3): 39-52.
55. San L, Arranz B, Martinez-Raga J,. Antipsychotic drug treatment of schizophrenic patients with substance abuse disorders. Eur Addict Res. 2007; 13: 230-243.
56. Zimmet SV, Strous RD, Burgess ES, et al. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. J Clin Psychopharmacol. 2000; 20: 94-98.
57. Schnell T, Koethe D, Krasnianski A, et al. Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: a randomized study. Am J Addict. 2014; 23: 308-312.
58. Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systemic review and meta-analysis. JAMA. 2014; 311 (18): 1889-1900.
59. Azorin JM, Simon N, Adida M, et al. Pharmacologic treatment of schizophrenia with comorbid substance use disorder. Exp Opin Pharm. 2016; 17 (2): 231-253.
60. McLoughlin BC, Pushpa-Rajah JA, Gillies D, et al. Cannabis and schizophrenia. Cochrane Database Syst Rev. 2014;(10): CD004837.
61. Marshall K, Gowing L, Ali R, et al. Pharmacotherapies for cannabis dependence. Cochrane Database Syst Rev 2014;(12): CD008940.
62. Hjorthoj CR, Fohlmann A, Larsen AM, et al. Specialized psychosocial treatment plus treatment as usual (TAU) versus TAU for patients with cannabis use disorder and psychosis: the CapOpus randomized trial. Psychol Med. 2013; 43 (7): 1499-1510.
63. Hunt GE, Siegfried N, Morley K, et al. Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev. 2013;(10): CD001088.
64. Brunette MF, Mueser KT, Drake RE,. A review of research on residential programs for people with severe mental illness and co-occurring substance use disorders. Drug Alcohol Rev. 2004; 23: 471-481.
65. McLellan AT, Lewis DC, O'Brien CP, et al. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000; 284 (13): 1689-1695.